Abstract: A mixture of minor diindole alkaloids from Vinca-containing vinblastine and 4-deacetoxy-vinblastine vines, are separated by subjecting the mixture to a deacetylation to correct the vinblastine to deacetyl-vinblastine prior to chromatographic separation of said mixture in a single stage.

Abstract: New compounds of the formula (I) ##STR1## wherein R.sub.1 and R.sub.2 each is a saturated or unsaturated, straight-chained or branched alkyl group, an aralkyl group, a saturated or unsaturated cycloalkyl group or an aryl group, orR.sub.1 and R.sub.2 together with the adjacent nitrogen atom forms a substituted or unsubstituted heterocyclic group with or without a further oxygen or nitrogen heteroatom, andR.sub.3 is hydrogen or an acyl group derived from a C.sub.1-18 carboxylic acid. The compounds are prepared by reducing the corresponding nitro compounds of the formula (II) ##STR2## and optionally acylating the obtained product. The compounds of the formula (I) and their acid addition salts and quaternary ammonium salts are active primarily in the induction of liver microsomal enzymes, but they also possess valuable antipyretic activity and a yohimbine lethality increasing effect characteristic of antidepressants.

Abstract: The invention relates to new 3-amino-17a-aza-D-homo-5.alpha.-androstane derivatives of the general formula I ##STR1## wherein R.sub.1 represents a methylene or an >N--CH.sub.3 group, and n stands for 1 or 2, and the acid addition salts and the quaternary salts of the general formula ##STR2## thereof, wherein R.sub.2 stands for an alkyl or alkenyl group having from 1 to 4 carbon atoms, and A represents a halogen atom, provided that if R.sub.1 stands for an >N--CH.sub.3 group, R.sub.2 is attached to the nitrogen of that >N--CH.sub.3 group. The new compound possess a non-polarizing neuromuscular blocking activity and have a short activity period.

Abstract: Ulcer production in animals is prevented during prolonged antiphlogistic treatment with ulcerogenic quantities of indomethacin by using it in a composition of 1 part of indomethacin to 7.5 to 25 parts, preferably 10 parts by weight of a salicylate. Indomethacin is the most potent ulcerating compound among approved non-steroid antiinflammatory agents.

Abstract: New 2-amino-cyclopent-1-ene-thiocarboxylic acid-disulfides of the general formula (I), ##STR1## wherein R is hydrogen, a C.sub.1-6 alkyl group having optionally a C.sub.1-4 alkoxy, hydroxy, carboxy and/or amino substituent, a C.sub.2-4 alkenyl group, a C.sub.3-8 cycloalkyl group or phenyl group, are prepared by oxidizing the respective 2-amino-cyclopent-1-ene-dithiocarboxylic acids of the general formula (II), ##STR2## wherein R is as defined above. The new compounds of the general formula (I) and their salts exert dopamine-.beta.-hydroxylase inhibiting effects and can be applied in the therapy.

Abstract: A method of treating mammalian noradrenaline malfunctions or dysfunction or effecting dopamine-.beta.-hydroxylase inhibition comprises administering an effective dose of an acid derivative of the formula (I), ##STR1## wherein R is C.sub.2-4 alkenyl, C.sub.3-8 cycloalkyl, benzyl or C.sub.1-6 alkyl which has a C.sub.1-4 alkoxy or a hydroxy substituent, or C.sub.2-6 alkyl with a carboxy and/or amino substituent, or C.sub.5 - or C.sub.6 -unsubtituted alkyl.

Abstract: A process for the preparation of alkaloids of the leurosine type having the formula I ##STR1## and the acid addition salts thereof. In the formula I R is hydrogen or methyl. The compounds prepared according to the invention are known compounds showing cytostatic activity.

Abstract: Ulcer production in animals is prevented during prolonged antiphlogistic treatment with ulcerogenic quantities of phenylbutazone by using it in a composition of 1 part of antiphlogistic to 0.2 to 50 parts by weight of alkali metal salicylate.

Abstract: 3-[4-(2'-Pyridyl)-piperazin-1-yl]-1-(3,4,5-trimethoxybenzoyloxy)-propane or a pharmaceutically acceptable acid-addition salt thereof in a composition with anti-arrhythmic activity.

Abstract: Leurosine derivatives of the formula (I), ##STR1## wherein R is hydrogen or formyl, or pharmaceutically acceptable acid addition salts thereof were prepared by oxidizing leurosine or an acid addition salt thereof, optionally formylating the thus-obtained product and then separating, and, if desired, converting any of the free bases into its acid addition salt. The new compounds of the invention possess strong cytostatic activity, and can be used in the human therapy with great advantage.

Abstract: New hydroxymethyl-pyridine esters of the formula (I) ##STR1## wherein R represents a 9-xanthenyl group or a phenyl group substituted by a halogen atom or a trifluoromethyl group or by an alkyl or alkoxy group, either having 1 to 4 carbon atoms, and pharmaceutically acceptable acid addition salts and quaternary salts thereof are prepared by acylating the corresponding hydroxymethyl pyridines with a carboxylic acid of the formula R--COOH, or with a reactive derivative thereof, and, if desired, converting the obtained product of the formula I into a pharmaceutically acceptable acid addition salt or quaternary salt thereof. The new compounds exert beneficial effects on functional disorders of the heart.

Abstract: The invention relates to novel peptides of formula (I),A-Try-B-Asp-Phg-NH.sub. 2 (I)whereinA is tert.-butoxycarbonyl-aminooxy-acyl, benzyloxycarbonyl-aminooxy-acyl, (aminooxy)-acyl or E-aminooxy-acyl, wherein E is benzoyl or straight-chained or branched C.sub.1-5 aliphatic acyl, andB represents methionyl, leucyl, norleucyl, norvalyl or 2-amino-decanoyl,or acid addition salts or complexes thereof. The novel compounds according to the invention exert gastrin effects and can be applied to advantage in the diagnostics and therapy. The novel compounds of formula (I) are prepared according to the invention by reacting a tetrapeptideamide of formula (II),H-Try-B-Asp-Phg-NH.sub. 2 (II)wherein B is as defined above, with an (aminooxy)-acyl containing compound of the general formula A.sub.1 -X, whereinA.sub.1 has the same meanings as A with the exception of the (aminooxy)-acyl, andX is hydroxy group, halogen, pivaloyloxy, a group of the formula R--O--CO.sub.

Abstract: New 2-amino-cyclopent-1-ene-thiocarboxylic acid-disulfides of the formula, ##STR1## wherein R is a C.sub.1-6 alkyl group having optionally a C.sub.1-4 alkoxy, hydroxy, carboxy and/or amino substituent, a C.sub.2-4 alkenyl group, or a C.sub.3-8 cycloalkyl group, are prepared by oxidizing the respective 2-amino-cyclopent-1-ene-dithiocarboxylic acids of the formula, ##STR2## wherein R is as defined above. The compounds of the formula (I) exert dopamine-.beta.-hydroxylase inhibiting effects and can be applied in therapy.

Abstract: 2-Amino-cyclopent-1-ene-1-dithiocarboxylic acid derivatives of the formula, ##STR1## wherein R is C.sub.2-4 alkenyl, or C.sub.1-6 alkyl group having optionally a C.sub.1-4 alkoxy, hydroxy, carboxy and/or amino substituent, with the proviso that if R is an unsubstituted alkyl group, this group contains at least 5 carbon atoms, are prepared by reacting 2-amino-cyclopent-1-ene-1-dithiocarboxylic acid or a salt thereof with an amine of the formula,R--NH.sub.2 (II)wherein R is as defined above. The new compounds of the invention exert dopamine-.beta.-hydroxylase inhibiting effects.

Abstract: Angiotensin II analog of the formula IX-Arg-Val-Tyr-Ile-His-Pro-Y (I)whereinX is a radical derived from an aliphatic .alpha.-aminooxy-carboxylic acid andY is a radical derived from an aliphatic .alpha.-amino-carboxylic acid,and acid addition salts and complexes thereof with antagonistic properties useful in the diagnosis and treatment of hypertensions depending on renin.

Abstract: Curare-type salts of the formula ##STR1## wherein Ac is an alkyl carbonyl group containing 1 to 4 carbon atoms in the alkyl moiety and one ofR.sub.1 and R.sub.2, is a methylene group and the other is a group of the formula >N--R.sub.2 wherein R.sub.2 is an alkyl group containing 1 to 3 carbon atoms,A is halogen andR.sub.3 is an alkyl group containing 1 to 4 carbon atoms, or an alkyl group; anda process for the preparation thereof are disclosed.

Abstract: New pharmacologically active octahydro-indolo[2,3-a]quinolizine derivatives of the formula ##STR1## wherein Q is hydrogen or an A--CH.sub.2 --CH.sub.2 -- group and A is cyano or -COOR, wherein R is C.sub.1-6 alkyl are prepared by reacting 2,3,4,6,7,12-hexahydro-indolo[2,3-a]quinolizine with a compound of the formula CH.sub.2 .dbd.

Abstract: Tumor inhibiting alkaloids are recovered from Vinca Rosea L. by a method which comprises extracting the dried leaves with a solvent selected from the group consisting of an alkanol having 1 to 5 carbon atoms, a mixture of an alkanol having 1 to 5 carbon atoms and a dilute, aqueous solution, benzene and benzene homologs; subsequently purifying the alkaloid extract obtained by a phase-change method between immiscible solvents, precipitating the main amount of dimeric alkaloids in form of their sulphuric acid addition salts, isolating leurosine, vincistine, vinblastine, desacetoxy-vinblastine, N-desmethyl-vinblastine and desacetyl-vinblastine from the salt mixture obtained, and then completing the separation and isolation of the remaining alkaloids by separation and isolation by adjusting the pH-value of the mother liquor, after precipitation and removal of the salt mixture, to 5.

Abstract: Peptides of the formula:A--Trp--B--Asp--Phe--NH--Ywherein A is tert.-butoxycarbonyl-aminooxy-acyl, benzyloxycarbonyl-aminooxy-acyl, (aminooxy)-acyl, or E-aminooxy-acyl, wherein E is benzoyl or straight-chain or branched C.sub.1-5 aliphatic acyl, B is methionyl, leucyl, norleucyl, norvalyl or 2-amino-decanoyl, and Y is hydrogen or carboxymethoxy, and pharmaceutically acceptable acid-addition salts or complexes thereof have gastric-acid secretion increasing effects.

Abstract: 5.alpha., 17B-Diacetoxy-6 -chloro-2.alpha., 3.alpha.; 16.alpha., 17.alpha.-diepoxy-androstane; 5.alpha., 17B-Dicetoxy-6 -chloro-androsta-2,16-diene; 5.alpha.-Hydroxy-6 -chloro-17-oxo-androst-2-ene or a like intermediate in the production of curare-like compounds is produced by reacting 5.alpha., 6B-dihydroxy-17-oxo-androst-2-ene with an organic sulfonic acid chloride. The obtained 5.alpha.- hydroxy-6B-chloro-17-oxo-androst-2-ene can then be reacted with the enol acetate of a ketone having 3 to 5 carbon atoms to yield 5.alpha., 17B-diacetoxy-6B-chloro-androsta-2,16-diene. The latter is treated to yield the corresponding diepoxide.